Theme |
Carcinogenesis Based on H. pylori-associated Gastritis -- Is Cancer Control Possible by the Eradication ? |
Title |
Effects of Helicobacter pylori Eradication on Gastric Cancer Development : New Opinion |
Author |
Takao Maekita |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Shotaro Enomoto |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Mikitaka Iguchi |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Hisanobu Deguchi |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Takeichi Yoshida |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Izumi Inoue |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Hideyuki Tamai |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Jun Kato |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
Author |
Masao Ichinose |
Depertment of Gastroenterology, Faculty of Medicine, Wakayama Medical University |
[ Summary ] |
Eradication of Helicobacter pylori (H. pylori) was thought to improve chronic active gastritis, prevent progression of atrophic gastritis, and to inhibit gastric cancer development by eliminating promoter effects. However, contrary to expectations, eradication did not dramatically inhibit gastric cancer in a human intervention study. Blind eradication treatment is unlikely to inhibit gastric cancer significantly at general population levels. "A point of no return" has been suggested, and because eradication is unlikely to result in the inhibition of gastric cancer in patients with severe atrophic gastritis, indications are necessary for identifying individuals who will benefit from eradication of H. pylori. Serum pepsinogen level has been strongly suggested to be effective as an indicator of patients who are at risk. |